Biology: Cellares Raises $257M to Industrialize Cell Therapy

Automated Cell Therapy Manufacturing: Cellares Secures $257M to Scale Global Production

Cellares has raised $257 million in Series D funding to complete the construction of automated cell therapy manufacturing plants in the U.S., Japan, and the Netherlands. The company’s proprietary “Cell Shuttle” platform integrates and automates the production process, aiming to significantly reduce labor costs, facility requirements, and the high failure rates typically associated with CAR T therapies. Having recently received the FDA’s first-ev…

Cellares raises $257M Series D to automate cell therapy manufacturing

The cell and gene therapy boom is running into its manufacturing bill.  Traditional production remains manual and expensive, which makes the ROI for many therapies murky at best. Venture funding in the sector has plunged more than 80% from its 2021 peak. Cellares is betting the path forward is industrial. The South San Francisco company… The post Cellares raises $257M Series D to automate cell therapy manufacturing appeared first on Drug Discove…

Exclusive: Cellares raises $257M to fund global expansion as it eyes 2027 IPO

Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public. Cellares aims to launch its commercial cell therapy manufacturing services in ...

Biology: Cellares Raises $257M to Industrialize Cell Therapy

What You Should Know The News: Cellares has raised $257M in Series D financing, bringing its total capital to $612 million. The round was co-led by BlackRock and Eclipse.The Tech: Cellares is building the world’s first IDMO (Integrated Development and Manufacturing Organization). Its Cell Shuttle and Cell Q platforms fully automate the manufacturing and quality control of cell therapies, replacing “artisanal” manual processes.The Scale: The comp…